EGI-1Homo sapiens (Human)Cancer cell line

Also known as: EGI1, Egi-1

🤖 AI SummaryBased on 5 publications

Quick Overview

EGI-1 is a human hepatobiliary cancer cell line derived from intrahepatic cholangiocarcinoma, used for studying cancer genetics...

Detailed Summary

EGI-1 is a human cell line derived from intrahepatic cholangiocarcinoma, a type of bile duct cancer. It is commonly used in research to study the genetic and molecular mechanisms underlying cholangiocarcinoma. This cell line has been characterized for its mutational profile, including mutations in IDH1 and IDH2, which are associated with metabolic and epigenetic changes in cancer cells. EGI-1 is also utilized in drug screening studies to evaluate the efficacy of targeted therapies, such as dasatinib, which shows hypersensitivity in IDH-mutant cancers. The cell line provides a valuable model for understanding the role of IDH mutations in cancer progression and for developing therapeutic strategies targeting these mutations.

Research Applications

Genetic and molecular profiling of cholangiocarcinomaDrug screening and targeted therapy developmentStudy of IDH mutations and their role in cancer progression

Key Characteristics

IDH1 and IDH2 mutationsSensitivity to dasatinib in IDH-mutant cancersModel for studying metabolic and epigenetic changes in cancer

Generated on 6/16/2025

Basic Information

Database ID	CVCL_1193
Species	Homo sapiens (Human)
Tissue Source	Bile duct[UBERON:UBERON_0002394]

Donor Information

Age	52
Age Category	Adult
Sex	Male

Disease Information

Disease	Cholangiocarcinoma
Lineage	Biliary Tract
Subtype	Extrahepatic Cholangiocarcinoma
OncoTree Code	EHCH

DepMap Information

Source Type	DSMZ
Source ID	ACH-001494_source

Known Sequence Variations

Type	Gene/Protein	Description	Zygosity	Note	Source
MutationSimple	TP53	p.Arg273His (c.818G>A)	Homozygous	-	Unknown, PubMed=16264262
MutationSimple	KRAS	p.Gly12Asp (c.35G>A)	Unspecified	-	PubMed=29786757

Haplotype Information (STR Profile)

Short Tandem Repeat (STR) profile for cell line authentication.

Amelogenin

X,Y

CSF1PO

12,13

D13S317

D16S539

11,12,13

D18S51

14,16

D19S433

14,15

D21S11

28,33.2

D2S1338

19,24

D3S1358

14,17

D5S818

D7S820

9,13

D8S1179

11,16

FGA

20,24,25

Penta D

7,9

Penta E

5,11

TH01

6,9

TPOX

8,11

vWA

17,18,19

Gene Expression Profile

Gene expression levels and statistical distribution

Loading cohorts...

Full DepMap dataset with combined data across cell lines

Loading gene expression data...

Publications

Generation of a biliary tract cancer cell line atlas reveals molecular subtypes and therapeutic targets.

Vazquez F., Getz G., Bardeesy N.M.

bioRxiv 2024:07.04.601970-07.04.601970(2024).

DOI PubMed PMC

Development and characterization of human primary cholangiocarcinoma cell lines.

Glaser S., Kennedy L., Francis H., Zhang W.-J., Alpini G.D., Ekser B.

Am. J. Pathol. 192:1200-1217(2022).

DOI PubMed PMC

RNA sequencing of hepatobiliary cancer cell lines: data and applications to mutational and transcriptomic profiling.

Umu S.U., Rounge T.B., Roessler S., Lorenzo-Bermejo J.

Cancers (Basel) 12:2510.1-2510.14(2020).

DOI PubMed PMC

Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens.

Stronach E.A., Saez-Rodriguez J., Yusa K., Garnett M.J.

Nature 568:511-516(2019).

DOI PubMed

An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.

Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.

Cancer Res. 79:1263-1273(2019).

DOI PubMed PMC

A landscape of pharmacogenomic interactions in cancer.";

Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.

Cell 166:740-754(2016).

DOI PubMed PMC

Isocitrate dehydrogenase mutations confer dasatinib hypersensitivity and SRC dependence in intrahepatic cholangiocarcinoma.

Bardeesy N.M.

Cancer Discov. 6:727-739(2016).

DOI PubMed PMC

Antitumor effect of the novel sphingosine kinase 2 inhibitor ABC294640 is enhanced by inhibition of autophagy and by sorafenib in human cholangiocarcinoma cells.

Zou X.-P., Thomas M.B., Smith C.D., Roberts L.R.

Oncotarget 7:20080-20092(2016).

DOI PubMed PMC

Signatures of mutation and selection in the cancer genome.";

Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.

Nature 463:893-898(2010).

DOI PubMed PMC